Almirall and Forest Laboratories have announced that a Phase 3 study of their aclidinium bromide DPI for the treatment of COPD produced significant improvement from baseline in FEV1 at clinical doses but underperformed when compared to placebo. Another Phase 3 double-blind study is still underway, and Forest Lab’s President Lawrence S. Olanoff expressed confidence that the results, which are expected in the first quarter of 2011, will be more in line with the promising results from previous studies. Read the company’s press release.
